TokenPost·
FDA Requires Vision-Risk Warnings Across the GLP-1 Drug Class
A review found 15 probable cases among 134,253 trial participants. A separate analysis found mixed results when comparing GLP-1 drugs with other diabetes treatments.
More news
- TokenPostTrump's Company Added 1,510 Bitcoin, Pushing Holdings Past 15,600 BTC
- TokenPostPieverse Leads Crypto Gainers With 30.63% Rise to $2.09
- TokenPostUK 10-Year Gilt Yield Falls 30 Basis Points Over Past Month
- TokenPostArbitrum Adds $64.2 Million in Weekly Stablecoin DEX Volume
- TokenPostSMQKE Frames Ripple’s XRP (XRP) Escrow as Price Protection
- TokenPostNvidia Directors Name Joon H. Kim to Conduct Jensen Huang Inquiry